Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

937
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
937
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

893
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
893
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

311
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
311
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

434
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
434
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

245
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
245

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing imatinib sampling strategies through a population approach: a crucial step to model-informed precision dosing validation for point-of-care therapeutic drug monitoring.

BMC pharmacology & toxicology·2026
Same author

Evaluating Bayesian Vancomycin Dosage Adjustment in Neonates: A Simulation-Based Virtual TDM Study.

Clinical pharmacokinetics·2026
Same author

Pelargonium sidoides extract (EPs® 7630) versus usual care for acute bronchitis in Swiss primary care (PHYTOBRONCH): a pragmatic, open-label, randomised controlled trial.

NPJ primary care respiratory medicine·2026
Same author

Population pharmacokinetics of encorafenib and binimetinib in real-world patients with BRAF<sup>V600E/K</sup>-mutant metastatic melanoma.

Cancer chemotherapy and pharmacology·2026
Same author

Model-Based Strategy for 6-Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6-TGN and 6-MMP Concentrations to Optimize Treatment.

Pediatric blood & cancer·2026
Same author

Challenges in performing clinical research on herbal products - experiences from Switzerland and the UK.

Frontiers in pharmacology·2026

Related Experiment Video

Updated: Mar 12, 2026

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.6K

Pharmacometrics-based decision tools facilitate mHealth implementation.

Fahima Nekka1, Chantal Csajka2, Mélanie Wilbaux3

  • 1a NSERC-Industrial Chair in Pharmacometrics, Full Professor, Faculty of Pharmacy , Université de Montréal , Montreal , Qc , Canada.

Expert Review of Clinical Pharmacology
|November 5, 2016
PubMed
Summary

Pharmacometrics enables personalized medicine by optimizing treatment strategies. Decision support tools, integrating scientific, technical, and regulatory aspects, facilitate efficient commercialization and patient care.

Keywords:
bench-to-bed-translationclinical pharmacologycomputer modelingdecision support toolsdigital technologymHealthpersonalised healthpharmacometricsprecision medicine

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

8.2K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Related Experiment Videos

Last Updated: Mar 12, 2026

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.6K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

8.2K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Area of Science:

  • Pharmacometrics
  • Digital Health
  • Personalized Medicine

Background:

  • Healthcare is shifting from a reactive, one-size-fits-all model to patient-centric, individualized medicine.
  • This evolution is propelled by scientific advancements and the digital revolution, particularly in quantitative treatment strategy evaluation.

Purpose of the Study:

  • To outline a framework for applying pharmacometrics-based decision support tools.
  • To present examples of these tools for patient monitoring and treatment individualization across all age groups.

Main Methods:

  • Review of pharmacometric approaches and decision support tool development.
  • Discussion of four key steps: scientific validation, technical options, regulatory considerations, and commercialization.
  • Presentation of case examples in neonates, children, and adults.

Main Results:

  • A four-step process for implementing pharmacometrics-based decision support tools is described.
  • Examples demonstrate the application of these tools for individualized patient care.
  • The integration of scientific, technical, and regulatory factors is crucial for successful implementation.

Conclusions:

  • User-friendly decision support tools are essential for advancing personalized medicine.
  • These tools will facilitate the adoption of mobile health (mHealth) strategies.
  • Pharmacometrics-driven tools promise significant benefits for pediatric and adult patients and their caregivers.